Evaluation of serum phosphopeptides as potential biomarkers of gastric cancer

A serum phosphopeptide (DpSGEGDFLAEGGGVR) was demonstrated to be a potential biomarker for gastric cancer diagnosis, particularly for early stage cases.

Download Full-text

Identification of Early Diagnostic and Prognostic Biomarkers via WGCNA in Stomach Adenocarcinoma

Frontiers in Oncology ◽

10.3389/fonc.2021.636461 ◽

2021 ◽

Vol 11 ◽

Author(s):

Ruoyue Tan ◽

Guanghui Zhang ◽

Ruochen Liu ◽

Jianbing Hou ◽

Zhen Dong ◽

...

Keyword(s):

Gastric Cancer ◽

Extracellular Matrix ◽

Early Detection ◽

Early Stage ◽

Gene Set Enrichment Analysis ◽

Stage I ◽

Tyrosine Kinase Receptor ◽

Stomach Adenocarcinoma ◽

Early Diagnostic ◽

Potential Biomarkers

Stomach adenocarcinoma (STAD) is a leading cause of cancer deaths, and the outcome of the patients remains dismal for the lack of effective biomarkers of early detection. Recent studies have elucidated the landscape of genomic alterations of gastric cancer and reveal some biomarkers of advanced-stage gastric cancer, however, information about early-stage biomarkers is limited. Here, we adopt Weighted Gene Co-expression Network Analysis (WGCNA) to screen potential biomarkers for early-stage STAD using RNA-Seq and clinical data from TCGA database. We find six gene clusters (or modules) are significantly correlated with the stage-I STADs. Among these, five hub genes, i.e., MS4A1, THBS2, VCAN, PDGFRB, and KCNA3 are identified and significantly de-regulated in the stage-I STADs compared with the normal stomach gland tissues, which suggests they can serve as potential early diagnostic biomarkers. Moreover, we show that high expression of VCAN and PDGFRB is associated with poor prognosis of STAD. VCAN encodes a large chondroitin sulfate proteoglycan that is the main component of the extracellular matrix, and PDGFRB encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor (PDGF) family. Consistently, Gene Ontology (GO) analysis of differentially expressed genes in the STADs indicates terms associated with extracellular matrix and receptor ligand activity are significantly enriched. Protein-protein network interaction analysis (PPI) and Gene Set Enrichment Analysis (GSEA) further support the core role of VCAN and PDGFRB in the tumorigenesis. Collectively, our study identifies the potential biomarkers for early detection and prognosis of STAD.

Download Full-text

Diagnostic value of macrophage inhibitory cytokine 1 as a novel prognostic biomarkers for early gastric cancer screening

10.21203/rs.3.rs-17962/v1 ◽

2020 ◽

Author(s):

Xin Ge ◽

Xiaolei Zhang ◽

Yanling Ma ◽

Shaohua Chen ◽

Zhaowu Chen ◽

...

Keyword(s):

Gastric Cancer ◽

Early Gastric Cancer ◽

Cancer Diagnosis ◽

Early Stage ◽

Precancerous Lesions ◽

Diagnostic Value ◽

Low Grade ◽

Serum Samples ◽

Early Screening ◽

Roc Curve Analysis

Abstract BACKGROUND Early diagnosis is very important to improve the survival rate of patients with gastric cancer, especially in asymptomatic participants. However, low sensitivity of common biomarkers has caused difficulties in early screening of gastric cancer. In this study, we explored whether MIC-1 can improve the detection rate of early gastric cancer.METHODS We screened 8,257 participants based on risk factors such as age, gender, and family history for physical examination including gastroscopy. Participant blood samples were taken for measure MIC-1, CA-199, CA72-4 and PG1/PG2 levels. The diagnostic performance of MIC-1 was assessed and compared with CA-199, CA72-4 and PG1/PG2, and its role in early gastric cancer diagnosis and the assessment of the risk of precancerous lesions have also been studied.RESULTS Based on endoscopic and histopathological findings, 55 participants had gastric cancer, 566 participants had low-grade neoplasia, 2605 participants had chronic gastritis. MIC-1 levels were significantly elevated in gastric cancer serum samples as compared to controls (p<0.001). The sensitivity of serum MIC-1 for gastric cancer diagnosis was much higher than that of CA-199 (49.1% vs. 20.0%) with similar specificities. Moreover, receiver operating characteristic (ROC) curve analysis also showed that serum MIC-1 had a better performance compared with CA-199, CA72-4 and PG1/PG2 in distinguishing early-stage gastric cancer (AUC: 72.9% vs. 69.5%, 67.5%, 44.0% respectively).CONCLUSIONS Serum MIC-1 is significantly elevated in most patients with early gastric cancer. MIC-1 can serve as a novel diagnostic marker of early gastric cancer and value the risk of gastric cancer.

Download Full-text

Hypermethylated DNA as potential biomarkers for gastric cancer diagnosis

Clinical Biochemistry ◽

10.1016/j.clinbiochem.2011.09.006 ◽

2011 ◽

Vol 44 (17-18) ◽

pp. 1405-1411 ◽

Cited By ~ 16

Author(s):

Yanan Zheng ◽

Lu Chen ◽

Jianfang Li ◽

Beiqin Yu ◽

Liping Su ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Diagnosis ◽

Potential Biomarkers

Download Full-text

Aberrant expression ofPlncRNA-1andTUG1: potential biomarkers for gastric cancer diagnosis and clinically monitoring cancer progression

Biomarkers in Medicine ◽

10.2217/bmm-2017-0090 ◽

2017 ◽

Vol 11 (12) ◽

pp. 1077-1090 ◽

Cited By ~ 18

Author(s):

Zohreh Baratieh ◽

Zahra Khalaj ◽

Mohammad Amin Honardoost ◽

Modjtaba Emadi-Baygi ◽

Hossein Khanahmad ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Progression ◽

Cancer Diagnosis ◽

Aberrant Expression ◽

Potential Biomarkers

Download Full-text

Potentials of neuron-specific enolase as a biomarker for gastric cancer

Tropical Journal of Pharmaceutical Research ◽

10.4314/tjpr.v19i3.7 ◽

2020 ◽

Vol 19 (3) ◽

pp. 505-511

Author(s):

Lingyun Wang ◽

Ruirui Hu ◽

Hongmei Liu ◽

Wen Li ◽

Lili Zhou ◽

...

Keyword(s):

Gastric Cancer ◽

Immunohistochemical Staining ◽

Early Stage ◽

Neuron Specific Enolase ◽

Tnm Staging ◽

Enzyme Linked Immunosorbent Assay ◽

Histological Changes ◽

Potential Biomarker ◽

Number Of Patients ◽

Significant Difference

Purpose: To investigate the potentials of neuron-specific enolase (NSE) as a biomarker for gastric cancer (GC). Methods: Gastric cancer (GC) patients (n = 412) who underwent gastrectomy were recruited over a 3- year period for this study. Their clinicopathological data such as age, sex, histological type, depth, tumor invasion, lymph node metastasis, and distant metastasis were analyzed. The patients were followed up for four years and the outcomes were also assessed. Histological changes in biopsies and levels of expression of NSE in biopsies and serum of patients were determined using immunohistochemical staining, western blotting and enzyme-linked immunosorbent assay (ELISA), respectively. Results: Immunohistochemical staining showed that NSE was differentially expressed in the cytoplasm of GC cells. Histological changes in biopsies of patients in the overexpression group were not significantly different from those of patients in under-expression group (p > 0.05). In NSE overexpression group, the number of patients in early stage GC subgroup (n = 186, 86.10 %, T1) were significantly higher than that in advanced GC subgroup (n = 124, 62.20 % T2–T4) (p < 0.05). However, in NSE under-expression group, there were more patients in advanced GC subgroup (n = 72, 37.70 %) than in early GC subgroup (n = 30, 13.80 %) (p < 0.05). Patients in NSE overexpression group survived longer than those in NSE under-expression group (p < 0.05). The level of expression of NSE significantly decreased with increase in TNM stage (p < 0.05). There was no significant difference in serum NSE level between GC patients and healthy control (p > 0.05). The results of the correlation analysis indicated that NSE levels were positively associated with GC. Conclusion: The results obtained in this study suggest that NSE could serve as a potential biomarker for GC. Keywords: Biomarker, Gastric cancer, Neuron-specific enolase, Overexpression, TNM staging

Download Full-text

Mir-421 in plasma as a potential diagnostic biomarker for precancerous gastric lesions and early gastric cancer

PeerJ ◽

10.7717/peerj.7002 ◽

2019 ◽

Vol 7 ◽

pp. e7002 ◽

Cited By ~ 5

Author(s):

Jianlin Chen ◽

Lihua Wu ◽

Yifan Sun ◽

Qi Yin ◽

Xianhua Chen ◽

...

Keyword(s):

Gastric Cancer ◽

Early Gastric Cancer ◽

Tumor Markers ◽

Cancer Progression ◽

Early Stage ◽

Precancerous Lesions ◽

Youden Index ◽

Gastric Lesions ◽

Precancerous Gastric Lesions ◽

Potential Biomarker

Objective MicroRNA (miR)-421 plays a key role in cancer progression. It has been reported that circulating miR-421may be a potential tumor marker for the diagnosis of several cancers. However, the role of miR-421 in plasma as a potential biomarker in the diagnosis of precancerous gastric lesions (Pre) and early-stage gastric cancer (GC) remains poorly understood. In this study, we investigated miR-421 in plasma as a novel potential biomarker for the detection of precancerous gastric lesions and early-stage (GC). Materials & Methods The miRNA content was determined by quantitative real-time polymerase chain reaction (qRT-PCR). MiR-421 content in all subjects was normalized by endogenous miRNA (miR-16). The diagnostic value of miR-421 for Pre and GC was assessed by comparing receiver operating characteristic (ROC) analysis with traditional tumor markers, including CEA, CA125, CA153, CA211 and CA50. The correlation between the expression of miR-421 and the pathological characteristics of Pre and GC was analyzed. Results Elevated expression of miR-421 in plasma can robustly distinguish the normal population from Pre and GC cases, especially in the early stages of gastric cancer cases (all p < 0.05). The ROC analyses showed that the area under the ROC curve (AUC), sensitivity, accuracy and Youden index of miR-421 were superior to traditional tumor markers (CEA, CA125, CA153, CA211, and CA50) in GC diagnosis, while its specificity was higher than CEA, CA153 and CA50 (all p < 0.05). MiR-421 in plasma had higher AUC value than AFP, CA153, CA211 and CA50 in the diagnosis of Pre (all p < 0.05), while specificity, accuracy and Youden index of miR-421 was only lower than CA211. The efficiency of miR-421 in the diagnosis of GC was significantly higher than that of CA211 and CA50, and it was significantly higher than CA153, CA211 and CA50 in the diagnosis of Pre (all p < 0.05). In addition, up-regulation of miR-421 occurred initially in precancerous gastric lesions as well as in the early stage of GC. Conclusions Overexpression of plasma miR-421 is a novel biomarker for the detection of precancerous lesions and early gastric cancer.

Download Full-text

Metabolomic profiling on plasma reveals potential biomarkers for screening and early diagnosis of gastric cancer and precancerous stages

10.21203/rs.3.rs-18127/v1 ◽

2020 ◽

Author(s):

Lijing Du ◽

Shasha Li ◽

Xue Xiao ◽

Jin Li ◽

Huizi Jin ◽

...

Keyword(s):

Gastric Cancer ◽

Early Diagnosis ◽

High Performance ◽

Diagnostic Performance ◽

Roc Analysis ◽

Characteristic Curve ◽

Disease Process ◽

Potential Biomarker ◽

Disease Stratification ◽

Potential Biomarkers

Abstract Background: Gastric cancer (GC) remains one of the most common cancers all over the world. The greatest challenge for GC is that it is often detected at advanced stages, leading to the loss of optimum time for treatment and giving rise to poor prognosis. Thus, there is a critical need to develop effective and noninvasive strategies for early diagnosis of the disease process. Methods: In total, 82 participants were enrolled in the study, including 50 chronic superficial gastritis (CSG) patients, 7 early gastric cancer (EGC) and 25 advanced gastric cancer (AGC) ones. Metabolites profiling on patient plasma was performed using ultra-high performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry ( UPLC-Q-TOF/MS ). Principal components analysis as well as orthogonal partial least squares-discriminant analysis was utilized to evaluate the variation on endogenous metabolites for GC patients and to screen potential biomarkers. Furthermore, the biomarker panels detected above were used to create logistic regression models, which discrimination efficiency and accuracy was ascertained by receiver operating characteristic curve (ROC) analysis. Metabolic pathways were carried out on MetaboAnalyst. Results: Totally 50 metabolites were detected differentially expressed among CSG, EGC and AGC patients. L-carnitine, L-proline, pyruvaldehyde, phosphatidylcholines (PC) (14:0/18:0), lysophosphatidylcholine (14:0) (LysoPC 14:0), lysinoalanine were defined as the potential biomarker panel for the diagnosis among CSG and EGC patients. Compared with EGC patients, 6 significantly changed metabolites, PC(O-18:0/0:0) and LysoPC(20:4(5Z,8Z,11Z,14Z)) were found to be up-regulated, whereas L-proline, L-valine, adrenic acid and pyruvaldehyde to be down-regulated in AGC patients. ROC analysis demonstrated a high diagnostic performance for metabolite panels with area under the curve (AUC) of 0.931 to 1. Moreover, the metabolomic pathway analysis revealed several metabolism pathway disruptions, including amino acid and lipid metabolisms, in GC patients. Conclusions: In this study, a total of six differential metabolites that contributed to GC and precancerous stages were identified, respectively. The biomarker panels further improve diagnostic performance for detecting GC, with AUC values of more than 93.1%. It indicated that the biomarker panels may be sensitive to the early diagnosis of GC disease, which can be used as a promising diagnostic and prognostic tool for disease stratification studies.

Download Full-text

Metabolomic profiling on plasma reveals potential biomarkers for screening and early diagnosis of intestinal-type gastric cancer and precancerous stages

10.21203/rs.3.rs-18127/v2 ◽

2020 ◽

Author(s):

Lijing Du ◽

Shasha Li ◽

Xue Xiao ◽

Jin Li ◽

Huizi Jin ◽

...

Keyword(s):

Gastric Cancer ◽

Early Diagnosis ◽

Pathway Analysis ◽

Roc Analysis ◽

Characteristic Curve ◽

Disease Process ◽

Intestinal Type ◽

Metabolic Pathway Analysis ◽

Potential Biomarker ◽

Potential Biomarkers

Abstract Background: Gastric cancer (GC) with majority of intestinal-type adenocaricinoma remains one of the most common cancers all over the world. GC faces a great challenge in the clinical diagnosis, that it often can be detected at advanced stages, and leads to the loss of optimum time for treatment and poor prognosis. Thus, there is a critical need to develop effective and noninvasive strategies for early diagnosis of the disease process. Methods: Totally, 82 participants were enrolled in the study, including 50 chronic superficial gastritis (CSG) patients, 7 intestinal-type early gastric cancer (EGC) and 25 intestinal-type advanced gastric cancer (AGC) ones. Metabolites profiling on patient plasma was performed using ultra-high performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF/MS). Principal components analysis, orthogonal partial least squares-discriminant analysis as well as Random forest were utilized to evaluate the variation on endogenous metabolites for intestinal-type GC patients and to screen potential biomarkers. Furthermore, the proposed biomarkers were used to create logistic regression models, which discrimination efficiency and accuracy was ascertained by receiver operating characteristic curve (ROC) analysis. Metabolic pathway analysis were carried out on MetaboAnalyst.Results: Totally 50 metabolites were detected with differentially expression among CSG, intestinal-type EGC and AGC patients. L-carnitine, L-proline, pyruvaldehyde, phosphatidylcholines (PC) (14:0/18:0), lysophosphatidylcholine (14:0) (LysoPC 14:0), lysinoalanine were defined as the potential biomarker panel for the diagnosis among CSG and EGC patients. Compared with EGC patients, 6 significantly changed metabolites, PC(O-18:0/0:0) and LysoPC(20:4(5Z,8Z,11Z,14Z)) were found to be up-regulated in AGC patients, whereas L-proline, L-valine, adrenic acid and pyruvaldehyde down-regulated. ROC analysis demonstrated a high diagnostic performance for metabolite panels with area under the curve (AUC) of 0.931 to 1. Moreover, the metabolomic pathway analysis revealed several metabolism pathway disorder, including amino acid and lipid metabolisms, in intestinal-type GC patients.Conclusions: In this study, a total of six metabolites were identified to contribute significantly to the diagnosis of intestinal-type GC and precancerous stages, respectively, and over 93.1% AUC value was achieved in AUC test on biomarker panels, It indicated that the biomarker panels are· sensitive to the early diagnosis of intestinal-type GC disease, which is expected to be developed as a promising diagnostic and prognostic tool for disease stratification studies.

Download Full-text

Metabolomic profiling on plasma reveals potential biomarkers for screening and early diagnosis of intestinal-type gastric cancer and precancerous stages

10.21203/rs.3.rs-18127/v3 ◽

2020 ◽

Author(s):

Lijing Du ◽

Shasha Li ◽

Xue Xiao ◽

Jin Li ◽

Huizi Jin ◽

...

Keyword(s):

Gastric Cancer ◽

Early Diagnosis ◽

Pathway Analysis ◽

Roc Analysis ◽

Characteristic Curve ◽

Disease Process ◽

Intestinal Type ◽

Metabolic Pathway Analysis ◽

Potential Biomarker ◽

Potential Biomarkers

Abstract Background: Gastric cancer (GC) with majority of intestinal-type adenocaricinoma remains one of the most common cancers all over the world. GC faces a great challenge in the clinical diagnosis, that it often can be detected at advanced stages, and leads to the loss of optimum time for treatment and poor prognosis. Thus, there is a critical need to develop effective and noninvasive strategies for early diagnosis of the disease process. Methods: Totally, 82 participants were enrolled in the study, including 50 chronic superficial gastritis (CSG) patients, 7 intestinal-type early gastric cancer (EGC) and 25 intestinal-type advanced gastric cancer (AGC) ones. Metabolites profiling on patient plasma was performed using ultra-high performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF/MS). Principal components analysis, orthogonal partial least squares-discriminant analysis as well as Random Forest were utilized to evaluate the variation on endogenous metabolites for intestinal-type GC patients and to screen potential biomarkers. Furthermore, the proposed biomarkers were used to create logistic regression models, which discrimination efficiency and accuracy was ascertained by receiver operating characteristic curve (ROC) analysis. Metabolic pathway analysis was carried out on MetaboAnalyst.Results: Totally 50 metabolites were detected with differentially expression among CSG, intestinal-type EGC and AGC patients. L-carnitine, L-proline, pyruvaldehyde, phosphatidylcholines (PC) (14:0/18:0), lysophosphatidylcholine (14:0) (LysoPC 14:0), lysinoalanine were defined as the potential biomarker panel for the diagnosis among CSG and EGC patients. Compared with EGC patients, 6 significantly changed metabolites, PC(O-18:0/0:0) and LysoPC(20:4(5Z,8Z,11Z,14Z)) were found to be up-regulated in AGC patients, whereas L-proline, L-valine, adrenic acid and pyruvaldehyde down-regulated. ROC analysis demonstrated a high diagnostic performance for metabolite panels with area under the curve (AUC) of 0.931 to 1. Moreover, the metabolomic pathway analysis revealed several metabolism pathway disorders, including amino acid and lipid metabolisms, in intestinal-type GC patients.Conclusions: In this study, a total of six metabolites were identified to contribute significantly to the diagnosis of intestinal-type GC and precancerous stages, respectively, and over 93.1% AUC value was achieved in AUC test on biomarker panels. It indicated that the biomarker panels are sensitive to the early diagnosis of intestinal-type GC disease, which is expected to be developed as a promising diagnostic and prognostic tool for disease stratification studies.

Download Full-text

UPDATE ON THE DIAGNOSIS AND MANAGEMENT OF EARLY GASTRIC CANCER

Journal of Medicine and Pharmacy ◽

10.34071/jmp.2014.6.1 ◽

2015 ◽

pp. 5-14

Author(s):

Van Huy Tran ◽

Quang Trung Tran

Keyword(s):

Gastric Cancer ◽

Early Gastric Cancer ◽

Early Diagnosis ◽

Cancer Diagnosis ◽

Good Prognosis ◽

Accurate Diagnosis ◽

White Light Endoscopy ◽

Key Factor ◽

Magnified Endoscopy ◽

Endoscopic Characteristics

The prognosis of gastric cancer depends principally upon an early diagnosis. An early and accurate diagnosis of gastric cancer needs some basic knowledges about the endoscopic characteristics of white light endoscopy, chromoendoscopy, magnified endoscopy, FICE and NBI…A strategy of screening is also a key factor for early diagnosis. The treatment of early gastric cancer by endoscopy techniques have showed more and more advantages. Beside of EMR, the technique of ESD is now applied more widely and lead to a very good prognosis and nearly a curative treatment for the patients with early gastric cancer. Key words: gastric cancer, early gastric cancer, diagnosis, endoscopy

Download Full-text